Oramed Pharmaceuticals Inc. is a biotechnology company focused on the research and development of oral drug delivery systems. The primary purpose of the company is to transform injectable treatments into oral forms, thereby aiming to enhance patient convenience and compliance. A notable highlight of Oramed's innovation is its proprietary Protein Oral Delivery (POD) technology, which facilitates the oral administration of proteins that traditionally require injections. This innovative approach has significant implications for therapeutics, particularly in areas like diabetes treatment, where oral insulin could potentially revolutionize disease management. Headquartered in Jerusalem, Israel, Oramed Pharmaceuticals Inc. holds a significant position in the healthcare sector, pushing forward the boundaries of medical treatment options through its cutting-edge research. Its development pipeline showcases the potential to reshape how chronic illnesses are managed, emphasizing the company's role as a pioneer in the oral delivery of biologics in the financial and healthcare markets.